Cytomegalovirus and paediatric renal transplants: Is this a current issue?

Nefrologia

Volumn 33, Issue 1, 2013, Pages 7-13

  Fijo López Viota, Julia ^a   Espinosa Román, Laura ^b   Herrero Hernando, Carlos ^c   Sanahuja Ibáñez, María J ^d   Vila Santandreu, Anna ^e   Praena Fernández, Juan M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

Cytomegalovirus; Paediatric renal transplant

Indexed keywords

ADOLESCENT; CHILD; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INCIDENCE; INFANT; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SHORT SURVEY; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; INFANT; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84873723056     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Sep.11470     Document Type: Short Survey

References (21)

1. Pérez-Sola MJ, Castón JJ, Solana R, Rivero A, Torre-Cisneros J. Indirect effects of cytomegalovirus infection in solid organ transplant recipients. Enferm Infecc Microbiol Clin 2008;26(1):38-47.
2. Nebbia G, Emery VC. Assessing the Full Impact of the Indirect Effects of Cytomegalovirus Following Solid Organ Transplantation. Trends in Transplant 2009;3(1):41-52.
3. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10(5):1228-37.
4. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, et al.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89(7):779-95.
5. Comoli P, Ginevri F. Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol 2012;27(5):705-17.
6. Martin JM, Danziger-Isakov LA. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation. Pediatr Transplant 2011;15(3):229-36.
7. Prestidge C, Lee-Son K, Matsuda-Abedini M, et al. CMV antiviral prophylaxis in renal transplantation. Pediatr Transplant 2011;15:S111.
8. Pescovitz MD. Valganciclovir in pediatric organ transplantation. Pediatric Health 2010;4(2):147-56.
9. NAPRTCS. 2010 Annual Transplant Report. Available at: https://web.emmes.com/study/ped/annlrept/2010_Report.pdf [Accessed: April 15, 2012].
10. Bock GH, Sullivan EK, Miller D, Gimon D, Alexander S, Ellis E, et al. Cytomegalovirus infections following renal transplantation -effects of antiviral prophylaxis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997; 11: 665-671.
11. Kranz B, Vester U, Wingen A-M, Nadalin S, Paul A, Broelsch CE, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplantation 2008;12:474-8.
12. Camacho-González AF, Gutman J, Hymes LC, Leong T, Hilinski JA. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 2011;91(2):245-50.
13. Renoult E, Clermont M-J, Phan V, Buteau C, Alfieri C, Tapiero B. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients. Pediatr Transplant 2008;12(4):420-5.
14. García-Testal A, Olagüe Díaz P, Bonilla Escobar BA, Criado-Álvarez JJ, Sánchez Plumed J. Análisis de infección por citomegalovirus y sus consecuencias en el trasplante renal: revisión de una década. Med Clin (Barc) 2011;137(8):335-9.
15. Kuo H-T, Ye X, Sampaio MS, Reddy P, Bunnapradist S. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis. Transplantation 2010;90:1091-8.
16. de la Torre-Cisneros J, Fariñas MC, Castón JJ, Aguado JM, Cantisán S, Carratalá J, et al. GESITRA-SEIMC/REIPI recommendations for the management og cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011;29(10):735-58.
17. Pérez JL. Técnicas de monitorización de la infección por citomegalovirus en los trasplantados de órgano sólido. La infección por citomegalovirus en el trasplante de órgano sólido: nuevas evidencias de un patógeno clásico. Enferm Infecc Microbiol Clin 2011;29 Suppl 6):18-23.
18. Lapidus-Krol E, Saphiro R, Amir J, Davidovits M, Steinberg R, Mor E, et al. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Pediatr Transplant 2010;14(6):753-60.
19. Robinson LG, Hilinski J, Graham F, Hymes L, Beck-Sague CM, Hsia J, et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002;6(2):111-8.
20. Melgosa Hijosa M, García Meseguer C, Peña García P, Alonso Melgar A, Espinosa Román L, Peña Carrión A, et al. Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrol 2004;61(4):246-52.
21. San Juan R, Yebra M, Lumbreras C, López-Medrano F, Lizasoain M, Meneu JC, et al. A new strategy of delayed long-term prophylaxis coul prevent cytomegalovirus disease in (D/R-) solid organ transplant recipients. Clin Transplant 2009;23(5):666-71.